Noticias del mercado de valores

Últimas noticias financieras · Actualizado Jul 25, 2026

D
▬ mixed

La industria de las criptomonedas logra una victoria ya que el proyecto de ley de regulación de la Ley de Claridad supera el obstáculo del Senado

Crypto industry scores win as Clarity Act regulation bill clears Senate hurdle

The panel is divided on the impact of the Clarity Act's committee passage. While some see it as a positive …

CNBC · May 14, 2026
BA
▬ mixed

China will order 200 Boeing jets, Trump tells Fox News

The panel is skeptical about the 200-jet Boeing order announced by Trump, citing lack of firm contracts, uncertainty about aircraft …

CNBC · May 14, 2026
U NVDA S ET
▼ bear…

Jim Cramer quiere comprar esta acción ahora un 10% por debajo de sus máximos. Aquí está el porqué

Jim Cramer wants to buy this stock now 10% below its highs. Here's why

The panel consensus is bearish on TJX Companies, with key risks including potential inventory sourcing issues and high valuation, and …

CNBC · May 14, 2026
CSCO
▬ mixed

El CEO de Cisco dice que la tecnología está entrando en un 'superciclo de redes' mientras las acciones suben un 14% por la fuerte demanda de IA

Cisco CEO says tech is entering a 'networking supercycle' as stock pops 14% on strong AI demand

Cisco's AI infrastructure guidance upgrade signals robust demand, but workforce cuts and limited visibility raise concerns about sustainability and margin …

CNBC · May 14, 2026
S U
▼ bear…

Bessent ve "sustancial desinflación" por delante mientras Warsh asume la Fed

Bessent sees 'substantial disinflation' ahead as Warsh takes over the Fed

The panel consensus is bearish, expecting sustained higher inflation and a 'higher for longer' interest rate environment, which will compress …

CNBC · May 14, 2026
CERS
▼ bear…

Cerebras casi duplica su debut en Nasdaq, superando una capitalización de mercado de 100 mil millones de dólares después de una exitosa IPO

Cerebras almost doubles in Nasdaq debut, topping $100 billion market cap after blockbuster IPO

Panel consensus is bearish on Cerebras' extreme valuation, high customer concentration, and geopolitical risks, despite its impressive tech and partnerships.

CNBC · May 14, 2026
F
▼ bear…

Ford se dispara un 20% en dos días. Podría ser una acción 'meme' de IA después de un cambio hacia la energía

Ford surges 20% in two days. It might be an AI 'meme' stock after energy pivot

The panel is bearish on Ford's recent surge, citing execution risks, geopolitical exposure, and unsustainable valuation. They agree that the …

CNBC · May 14, 2026
S U
▼ bear…

El jefe de la Patrulla Fronteriza de EE. UU., Mike Banks, renuncia

U.S. Border Patrol Chief Mike Banks resigns

The resignation of Chief Mike Banks at the U.S. Border Patrol, amidst political volatility and recent misconduct allegations, signals operational …

CNBC · May 14, 2026
S U
▼ bear…

China trabajará tras bambalinas para ayudar a reabrir el Estrecho de Ormuz, dice Bessent

China will work behind the scenes to help reopen the Strait of Hormuz, Bessent says

The panel is bearish on the energy sector (XLE) due to the high probability of diplomatic failure in resolving the …

CNBC · May 14, 2026
▬ mixed

El viaje de Musk a China durante el juicio de OpenAI provoca una disculpa del abogado por la ausencia del CEO

Musk's China trip during OpenAI trial prompts apology from his lawyer for CEO's absence

The panelists agree that Musk's decision to attend a geopolitical event during a high-stakes trial carries significant risks, primarily related …

CNBC · May 14, 2026
P S
▬ mixed

Goldman dice que el 'desplome alcista' de las acciones tecnológicas es una señal de aún más ganancias por venir

Goldman says tech stock 'up crash' is sign of even more gains to come

The panelists debated Goldman's 'up crash' thesis, with most expressing caution due to high valuations, concentration risks, and potential unwind …

CNBC · May 14, 2026
BIIB
▼ bear…

Biogen avanza un fármaco para el Alzheimer a un ensayo de fase tardía a pesar de datos decepcionantes

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Biogen's push for Phase 3 on diranersen is risky due to lack of dose-response in Phase 2, echoing Aduhelm's issues, …

CNBC · May 14, 2026